The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients.
Changchun Deng
No relevant relationships to disclose
Jennifer Effie Amengual
No relevant relationships to disclose
Marshall T. Schreeder
No relevant relationships to disclose
Sean Clark-Garvey
No relevant relationships to disclose
Molly Patterson
No relevant relationships to disclose
Hari Miskin
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Peter Sportelli
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Owen A. O'Connor
No relevant relationships to disclose